Benitec Biopharma Inc. (BNTC) compared with its closest peers (PRLD, MPLT, EVMN, XOMA, RZLT). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $528.30M | -2.2 |
| MapLight Therapeutics, Inc. (MPLT) | $523.89M | -0.9 |
| Evommune, Inc. (EVMN) | $506.27M | -1.6 |
| XOMA Royalty Corp. (XOMA) | $505.65M | 16.8 |
| Rezolute, Inc. (RZLT) | $490.13M | -4.5 |
| Relmada Therapeutics, Inc. (RLMD) | $487.74M | -3.3 |
| Puma Biotechnology, Inc. (PBYI) | $476.97M | 17.9 |
| BioAge Labs, Inc. (BIOA) | $435.33M | -5.9 |
| Atea Pharmaceuticals, Inc. (AVIR) | $434.71M | -1.8 |
| Foghorn Therapeutics Inc. (FHTX) | $420.74M | -4.5 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
BNTC overview · BNTC earnings · BNTC financials · BNTC KPIs · BNTC investor relations · BNTC ownership · BNTC filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.